Faruqi and Faruqui, LLP Logo
Share this page

American Renal Associates Holdings, Inc. (ARA)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In American Renal Associates Holdings, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at American Renal Associates Holdings, Inc. (“American Renal” or the “Company”) (NYSE:ARA).

The investigation focuses on whether the Company and its executives violated federal securities laws by engaging in potentially fraudulent billing practices in order to boost profits.

Specifically, on January 3, 2017, the Company received a subpoena from U.S. Department of Justice, dated December 30, 2016, requesting information relating to: (1) topics related to applicable healthcare laws for period from January 1, 2013 through the present; (2) the Company’s interactions with the American Kidney Fund.  The American Kidney Fund has come under accusations of steering patients away from Medicare and Medicaid programs into higher paying Affordable Care Act programs.

Take Action

If you invested in American Renal stock or options and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding American Renal’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    American Renal Associates Holdings, Inc. (ARA)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 01/09/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.